
Seawolf Therapeutics
Biotech · Gene Therapy · Pharma
Seawolf Therapeutics launches with $100M, up to $1.2B Sanofi deal
November 16, 2026
Raised
$100M
Big Pharma itself is now bankrolling the next attempt to crack repeat-dose gene therapy without using a virus.
- Seawolf Therapeutics emerged from stealth with $100 million in seed and Series A funding led by founding investor Versant Ventures, alongside a research collaboration and exclusive license deal with Sanofi worth up to $1.2 billion in milestones plus tiered royalties.
- The San Diego biotech, founded in 2021 and led by CEO Elizabeth Alcamo, builds DNA-based medicines using TRIDENT, a lipid nanoparticle platform designed to deliver DNA payloads repeatedly instead of the one-shot dosing typical of viral gene therapies.
- Series A backers beyond Versant include MPM BioImpact, Novartis Venture Fund, Eli Lilly, CRISPR Therapeutics, Sixty Degree Capital, Alexandria Venture Investments and the National Bleeding Disorders Foundation's venture arm, Pathway to Cures.
- The Sanofi pact is a multi-target research and exclusive license agreement focused on bleeding disorders and other undisclosed indications, with Seawolf eligible for up to $1.2 billion in milestones plus royalties on any approved products.
- Seawolf's lead program targets metabolic diseases and has reportedly reached Development Candidate stage, with animal data showing sustained protein expression above therapeutic levels in primates at safe, well-tolerated doses.
- Viral gene therapies like AAV typically allow only a single dose before the immune system blocks repeat treatment, a limitation that has stymied the field and is the exact problem Seawolf's non-viral approach aims to solve.
- Having four major pharma players as both investors and a licensing partner at launch signals strong industry conviction that redosable DNA delivery could unlock chronic-disease treatment beyond rare, one-time viral gene therapy use cases.
Lead Investors
Versant Ventures